Development of a Novel Mouse Anaphylaxis Model Produced by Intermittent Intravenous Injections of Ovalbumin without Adjuvant

This study was performed to develop mouse anaphylaxis model using ovalbumin (OA) as an antigen, with no adjuvant, and an intravenous route of administration. OA at dose levels from 0.5 to 500 mg/kg was injected 3 times into the tail vein of female CD-1 (ICR) mice at 4-day intervals. Clinical signs and extravasation of Evans blue dye (vascular permeability) were observed, serum histamine levels and airway resistance were measured, and...